179 related articles for article (PubMed ID: 8624534)
1. [Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Barthélémy Y; Colombel M; Gasman D; Patard JJ; Chopin D; Abbou CC
Prog Urol; 1996 Feb; 6(1):93-7. PubMed ID: 8624534
[TBL] [Abstract][Full Text] [Related]
2. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
3. [An unusual presentation of prostate cancer].
Joual A; Rabii R; Aboutaeib R; el Moussaoui A; Benjelloun S
Ann Urol (Paris); 1996; 30(5):262-3. PubMed ID: 8975593
[TBL] [Abstract][Full Text] [Related]
4. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
[TBL] [Abstract][Full Text] [Related]
5. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
[TBL] [Abstract][Full Text] [Related]
6. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
[TBL] [Abstract][Full Text] [Related]
9. Undetectable prostate-specific antigen response with bicalutamide withdrawal phenomenon.
El-Gabry EA; Strup SE; Gomella LG
Tech Urol; 2000 Sep; 6(3):221-2. PubMed ID: 10963494
[TBL] [Abstract][Full Text] [Related]
10. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports].
Kobayashi S; Tsukamoto T; Tohsaka A; Tohma T
Hinyokika Kiyo; 2008 Jun; 54(6):423-6. PubMed ID: 18634439
[TBL] [Abstract][Full Text] [Related]
11. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
12. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate.
Akakura K; Akimoto S; Ohki T; Shimazaki J
Urology; 1995 Apr; 45(4):700-4; discussion 704-5. PubMed ID: 7536369
[TBL] [Abstract][Full Text] [Related]
13. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails.
Kassouf W; Tanguay S; Aprikian AG
J Urol; 2003 May; 169(5):1742-4. PubMed ID: 12686822
[TBL] [Abstract][Full Text] [Related]
14. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
16. [Basic principles and initial results of adjuvant hormone therapy and irradiation of prostatic carcinoma].
Dearnaley DP; Shearer RJ; Ellingham L; Gadd J; Horwich A
Praxis (Bern 1994); 1997 Nov; 86(48):1895-901. PubMed ID: 9480509
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
18. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
Copp H; Bissonette EA; Theodorescu D
Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
[TBL] [Abstract][Full Text] [Related]
19. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
20. [Antiandrogen withdrawal syndrome].
Akimoto S
Nihon Rinsho; 1998 Aug; 56(8):2135-9. PubMed ID: 9750522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
